Eflornithine hydrochloride cream for hirsutism - horizon scanning review

Record ID 32001000991
Authors' objectives:

To summarise the current research evidence on the effectiveness of eflornithine hydrochloride cream for hirsutism.

Authors' recommendations: Eflornithine cream, a new treatment for hirsutism in woman is in the final stages of development. There is evidence of efficacy although treatment needs to be continued for long-term effectiveness. - Clinical impact: The introduction of eflornithine may have a significant impact on individual women but is likely to have very little overall clinical impact. - Service impact: The use of eflornithine to treat facial hirsutism will have little service impact, although more women with hirsutism may re-present to primary care and dermatologist once an effective therapy is available. - Patient issues: There is the risk medicalisation of an issue not previously in the clinical sphere with the introduction of eflornithine. - Financial and overall NHS impact: It is not possible to estimate the financial impact on the NHS. Eflornithine is likely to be a substitute for other therapies in some instances, and is a long-term treatment.
Authors' methods: Overview
Project Status: Completed
Year Published: 2001
URL for published report: http://www.hsric.nihr.ac.uk/search
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Eflornithine
  • Hirsutism
  • Women
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name: c.packer@bham.ac.uk
Contact Email: c.packer@bham.ac.uk
Copyright: National Horizon Scanning Centre
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.